MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
56.62
-0.70
-1.22%
After Hours: 56.50 -0.12 -0.21% 18:00 06/08 EDT
OPEN
57.20
PREV CLOSE
57.32
HIGH
58.00
LOW
55.36
VOLUME
1.00M
TURNOVER
--
52 WEEK HIGH
109.00
52 WEEK LOW
7.99
MARKET CAP
1.91B
P/E (TTM)
-6.7269
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NKTR last week (0601-0605)?
Weekly Report · 19h ago
Nektar Stockholders Approve Governance and Incentive Plan Changes
TipRanks · 3d ago
Nektar grants inducement stock options for 11,900 shares at $69.49 each
PUBT · 5d ago
NEKTAR THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
Nektar management to meet with Piper Sandler
TipRanks · 06/01 15:48
Weekly Report: what happened at NKTR last week (0525-0529)?
Weekly Report · 06/01 09:40
Nektar Therapeutics to present at Jefferies Global Healthcare Conference via webcast
PUBT · 05/27 22:16
Nektar Therapeutics interim CFO Linda M. Rubinstein files initial beneficial ownership statement
PUBT · 05/26 22:20
More
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Webull offers Nektar Therapeutics stock information, including NASDAQ: NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.